Skip to main content

Table 1 Study visit schedule: BENEFIT-Korea study

From: Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Variable Visit 1 (baseline) Visit 2 (follow-up) Visit 3 (follow-up/last visit)
Schedule (wk) 0 12 ± 2a 24 ± 2 a
Informed consent form   
Inclusion/exclusion criteria   
Patient demographics   
Height/weight/waist sizeb
History of previous anti-hypertensive drugs   
Medical historyc   
Administrative status of nebivolol
Concomitant medications
Laboratory testd
Blood pressure measuree
Safety assessment  
  1. aPatients were allowed ±2 weeks period from the designated schedules for follow-up visits. bHeight was measured only at baseline (height, weight, and waist size) was recorded up to one decimal. cPast medical history and present medical history within 6 months from baseline were recorded. In case a medical history was collected after baseline, it was recorded in the safety analysis set. dGlucose (HbA1c, fasting blood sugar), total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and other laboratory tests, when done, were recorded. Of the laboratory test results collected, the values pointing to adverse events were recorded in the safety analysis set. eBlood pressure was measured when subjects were stable - mean seated trough cuff blood pressure was measured